Synthesis of uniform cyclodextrin thioethers to transport hydrophobic drugs

  1. ,
  2. and
Organic Macromolecular Chemistry, Saarland University, Campus C4.2, 66123 Saarbrücken, Germany
  1. Corresponding author email
Associate Editor: S. C. Zimmerman
Beilstein J. Org. Chem. 2014, 10, 2920–2927.
Received 01 Aug 2014, Accepted 23 Nov 2014, Published 09 Dec 2014
Full Research Paper
cc by logo


Methyl and ethyl thioether groups were introduced at all primary positions of α-, β-, and γ-cyclodextrin by nucleophilic displacement reactions starting from the corresponding per-(6-deoxy-6-bromo)cyclodextrins. Further modification of all 2-OH positions by etherification with iodo terminated triethylene glycol monomethyl ether (and tetraethylene glycol monomethyl ether, respectively) furnished water-soluble hosts. Especially the β-cyclodextrin derivatives exhibit very high binding potentials towards the anaesthetic drugs sevoflurane and halothane. Since the resulting inclusion compounds are highly soluble in water at temperatures ≤37 °C they are good candidates for new aqueous dosage forms which would avoid inhalation anaesthesia.


Cyclodextrins (CDs) are cyclic oligomers of α-1,4-linked glucose units. Those CDs consisting of 6, 7, and 8 glucose units are called α-, β- and γ-CD, respectively [1]. CDs are well known to increase the bioavailability of active pharmaceutical ingredients (APIs) [2,3], and they are readily available in pharmaceutical purity and industrial quantities. Furthermore, they are water soluble and regarded as non-toxic in case of α- and γ-CD [4,5], while β-CD shows some toxic effects such as haemolysis at high concentrations [6].

CDs are generally employed to increase the bioavailability of those APIs scarcely soluble in water [7]. The observed solubilization of an API is generally based on the complexation of the hydrophobic part of the API molecule within the CD cavity [3]. There are several formulations of APIs containing CDs on the market, such as prostaglandine/α-CD [8], and piroxicam/β-CD [9].

Further application of native CDs for the delivery of hydrophobic drugs is often hampered by aggregation [10], and generally by poor solubility of the formed inclusion compounds. As a consequence, the phase solubility isotherm shows saturation behaviour, so-called B-type curves [11,12]. Therefore many CD derivatives have been synthesized to overcome this problem [1,12,13]. Statistical β-CD derivatives, such as hydroxypropyl-β-CD [14], methylated β-CD [15], and sulfobutyl-β-CD [16] are indeed in use, but quality control for such mixtures of compounds remains a difficult issue [17,18]. Also binding potentials of statistical β-CD derivatives like hydroxypropyl-β-CD are often smaller than those of native β-CD [19].

We recently found out that full methylation of all secondary hydroxy groups of β-CD causes a significant drop of binding potential, while substitution at the primary site does not alter the binding potential or even increases it [20]. Especially substitution of all primary hydroxy groups by thioether groups gives rise to compounds with very high binding potentials due to the higher hydrophobicity of sulfur compared to oxygen [21-23]. The octa-substituted carboxyethyl thioether of γ-CD is already in use under the name sugammadex (Bridion®) for the reversal of neuromuscular blockade, making use of its extremely high affinity towards rocuronium [24,25]. Furthermore, hydrophilic γ-CD thioethers show high affinities to other guests such as polycyclic aromatic hydrocarbons [26], botulin [27,28], and fullerene C60 [29].

Hydrophilic β-CD thioethers also tightly complex volatile benzene derivatives leading to a significant decrease of their vapour pressure [30]. Therefore we were encouraged to investigate the inclusion of volatile hydrophobic APIs, e.g., sevoflurane, in CD thioethers. Sevoflurane, a versatile inhalational anaesthetic [31], was already included in native CDs and hydroxypropyl-β-CD, but these complexes are either nearly insoluble in water or the binding constants are rather low [32-34].

We focussed our effort on the design of hydrophilic and/or amphiphilic CD thioethers, because only amphiphilic molecules can form [35,36] or incorporate into bilayer membranes [37,38]. Amphiphilic CD carriers can enter a bilayer membrane to support the API to overcome cellular barriers, such as the intestinal barrier [39] or the blood-brain barrier (BBB) [40]. Long alkyl chains (C4–C12) have already been attached via thioether or sulfoxide linkages to all primary positions by Kawabata and Ling et al. to form hydrophobic β-CD derivatives [41,42]. Mazzaglia et al. reported on amphiphilic β-CD derivatives with alkyl chains (C2–C16) connected by the thioether linkages to the primary site and a statistical substitution with oligoethylene glycol at secondary sites [43]. Becker et al. describe similar hosts with 2,2,2-trifluoroethyl groups at all primary sites and also oligoethylene glycol at secondary sites [44]. In both latter cases statistical CD derivatives have been employed, where both the lengths of the oligoethylene oxide side chains and their locations were scattered.

Herein, we report on the synthesis of water soluble CD derivatives (Scheme 1) with well-defined molecular structure and high binding affinities towards volatile anaesthetic APIs.


Scheme 1: Synthetic route to neutral water-soluble CD thioethers.

Results and Discussion

Heptakis-6-deoxy-6-bromo-β-CD, synthesized according to Defaye et al., was reacted with sodium methanethiolate, and ethanethiolate, respectively [45]. The reaction was performed in DMF solution leading to the corresponding thioethers 1b1/1b2 in excellent yields (up to 92%). Afterwards, these thioethers 1b1/1b2 were hydroxyethylated with ethylene carbonate to the water soluble derivatives 2b1/2b2 according to Mazzaglia et al. [43]. The ESI MS of 2b1 (Figure 1) showed a rather broad molecular weight distribution typical for CD derivatives with statistical substitution pattern. On the other hand, nearly uniform CD derivatives were synthesized by regioselective deprotonation of all 2-OH positions with NaH in DMF solution according to Tian and D’Souza [46], and subsequent complete alkylation with I-(CH2-CH2-O)n-CH3 (n = 3,4) for 4–7 d at 60–80 °C. The resulting derivatives 3 and 4 were isolated by liquid–liquid extraction at 50 °C with a Kutscher–Steudel extractor and subsequent column chromatography. Yields were high as shown in Table 1. The ESI MS of 3b1 (Figure 1) showed a significantly lower polydispersity than 2b1. Also the 1H NMR spectrum of 3b1 was much better resolved than the one of the statistical derivative 2b1 due to its homogenous substitution pattern and uniform lengths of the oligoethylene oxide groups (Figure 2).


Figure 1: ESI MS spectra of CD derivatives 2b1 (left) and 3b1 (right).

Table 1: List of the synthesized CD derivatives and their lower critical solution temperatures (LCST).

  Ring size R6 R2 Yield [%] LCST [°C]
3a1 6 SMe (CH2CH2O)3Me 42% 43
4a1 6 SMe (CH2CH2O)4Me 10%a 65
3b1 7 SMe (CH2CH2O)3Me 68% 42
3b2 7 SEt (CH2CH2O)3Me 89% 61
4b1 7 SMe (CH2CH2O)4Me 14%a 54
3c1 8 SMe (CH2CH2O)3Me 89% 49

aLoss of compound during ultrafiltration.


Figure 2: 1H NMR spectra of a) the statistical CD derivatives 2b1 and b) the corresponding uniform derivative 3b1 in DMSO-d6 (numbers in red are the integrals of the respective signals).

All β-CD derivatives 2, 3 and 4 were indeed highly soluble in water at 25 °C but upon heating the clear solutions turned turbid at a certain temperature and the compounds precipitated. The observed phase separation at the so-called lower critical solution temperature (LCST) is typical for uncharged polymeric amphiphiles, such as methyl cellulose [47], poly(N-isopropylacrylamide) (pNiPAAm) [48], and also for methylated CDs [49], and CDs completely modified with oligoethylene glycol units [50]. While the LCST transition of the statistical derivative 2b1 was within a rather broad temperature range (30–40 °C), the uniform derivative 3b1 showed a sharp transition at 42 °C (Figure 3). The LCST was only scarcely dependent on the ring size of CD but increased with the length of the hydrophilic oligoethylene oxide chain, as listed in Table 1. The LCST should be beyond 40 °C for being applicable for the delivery of drugs into a mammalian body.


Figure 3: Transmission (λ = 670 nm) of aqueous solutions (1.0 wt %) of 2b1 (red) and 3b1 (blue).

Investigation of the inclusion of sevoflurane

The inclusion of the anaesthetic sevoflurane by our hosts was investigated by the measurement of the vapour pressure of the guest by gas chromatography as a function of the host concentration as described by Armstrong [51] and Fourmentin et al. [30,52]. As shown in Figure 4, the vapour pressure of the guest sevoflurane significantly drops due to complexation by host 3b1.


Figure 4: Decay of the relative vapour pressure A/A0 as function of the host concentration 3b1 measured by GC headspace; the curve was fitted according to Equation 1.

The corresponding binding constant K was calculated from the hyperbolic decay of the area A of the sevoflurane signal with the total concentration of the CD derivative [CD]0 by non-linear regression according to Equation 1, as described previously in this journal [30]. The Henry constant was determined according to a known GC method [30] to kH = 2.0 at 25 °C and kH = 3.05 at 37 °C in good agreement with literature data [53]. The occupancy x of employed CD host by the guest was calculated by the law of mass action according to Equation 2. The solubility of the free guest sevoflurane in water [G] = 5.4 mM at 25 °C was calculated by the ideal gas law from its Henry constant and vapour pressure p = 263 mbar [54,55], according to Equation 3:


Commercially available native CDs and β-CD derivatives showed rather poor affinities to sevoflurane, as shown in Table 2. Among the native CDs β-CD had far the highest binding constant which was attributed to the best space filling of this host by sevoflurane. We recently demonstrated also for other guests that space filling has a very significant influence on the binding constants [30]. We found indeed an even higher binding constant for heptakis-2,6-di-O-methyl-β-CD (DIMEB), but medical applications remain questionable for this host because of its known high toxicity [6]. On the other hand, heptakis-2,3,6-tri-O-methyl-β-CD (TRIMEB) and the less toxic derivative hydroxypropyl-β-CD performed much worse. The low binding potential of TRIMEB was already found for other guests and can be attributed to the lack of intramolecular hydrogen bonds stabilizing the CD framework.

Table 2: Binding data for sevoflurane in native CDs and commercial CD derivatives at 25 °C.

Host K [L/mol] Occupancy x [mol %]
α-CD 18 9
β-CD 150 45
γ-CD 9 5
DIMEB 713 79
TRIMEB 27 13
HP-β-CD 163 47

The new hydroxyethylated CD thioethers, listed in Table 3, generally showed higher binding constants than the respective native CDs. The higher binding potential of CD thioethers was already found for other guests as well [21-23]. The binding constants of the α-CD derivatives 3a1 and 4a1 were much lower than the ones of the corresponding β-CD derivatives 3b1 and 4b1 which can be again rationalized by the better space filling of the seven membered rings by sevoflurane. The binding constant decreased with increasing lengths of the alkyl substituents at the sulfur atoms as well as with the lengths of the oligoethylene oxide chains. This fact was attributed to an increasing loss of entropy upon complexation of the guests. The longer the substituents the higher the conformational freedom of the host leading to higher intrinsic entropy. Also the two statistical derivatives, 2b1 and 2b2 showed somewhat lower binding constants than the regioselectively modified derivatives 3, which might be due to a smaller amount of residual secondary hydroxy groups known to stabilize the CD framework by intramolecular hydrogen bonds [20]. Among the CD thioethers 3b1 performed best reaching occupancies close to 100%.

Table 3: Binding data for sevoflurane in the new CD thioethers at 25 °C.

Host K [L/mol] Occupancy x [mol %]
3a1 64 26
4a1 9 5
2b1 2270 92
2b2 263 59
3b1 2801 94
3b2 286 61
4b1 722 80

Although all binding measurements were already performed under physiological pH and ionic strength, we were interested in the binding potential of the best host 3b1 approaching in vivo conditions to estimate the performance of this CD derivative for the delivery in the bodies of animals or humans. As anticipated, the binding constant slightly dropped in 5 wt % albumin solution and further dropped in human serum (Table 4). At 37 °C a further decrease of K was observed, but it still remained rather high. The occupancy of 3b1 was still 87 mol % in human serum at body temperature. Therefore this compound should be well suitable for the delivery of sevoflurane. Potentially oral aqueous dosage forms can be developed for both anaesthesia and the treatment of pain. 3b1 is also able to complex other hydrofluoric anaesthetics, like halothane [54], where the binding constant K = 9090 L/mol (occupancy of the host 98%) was even higher than for sevoflurane.

Table 4: Binding data for sevoflurane in 3b1 for various media and temperatures.

Medium Temperature
Occupancy x
[mol %]
albumina 25 2175 92
human serum 25 1802 90
water 37 1427 88
albumina 37 1382 88
human serum 37 1331 87

a5 wt %.


The water-soluble β-CD thioether 3b1 with the smallest possible substituents at both the sides of the CD torus showed the highest binding affinities for the anaesthetic APIs sevoflurane and halothane, much higher than native CDs and known CD derivatives. Since the LCST is sufficiently higher than body temperature, 3b1 is a very promising candidate for oral or intravenous delivery of these anaesthetics.


Methods. Characterization of all products was operated using NMR and ESIMS spectroscopy. All NMR spectra including 1H, 13C, H,H-COSY and C,H-COSY were measured at room temperature by a BrukerBioSpin spectrometer Magnet System 400 MHz Ultra shield plus (1H: 400 MHz, 13C: 100.6 MHz). The chemical shifts are given in parts per million (ppm) in relation to the corresponding solvent signal. The data analysis was performed with SpecManager included in ACDLabs 10.0 from Advanced Chemistry Development Inc., Toronto, Ontario, Canada. The proton and carbon atoms of the glucose units were marked with 1, 2, 3 etc. starting from the anomeric proton/carbon. The multiplicities were assigned as follows: s for singlet, d for doublet, t for triplet, bs for broad signal and m for multiplet. Mass spectra were recorded by a LC–MS spectrometer ZQ-4000 from Waters GmbH, Eschborn, Germany, operated in ESI+ and ESI mode.

Some products were purified by cross-flow nanofiltration using a membrane called Mini Mate TPP Capsule from Pall, Crailsheim, Germany, further a membrane called Omega with a Cut-off of 650 Da was used. Freeze-drying was carried out with a lyophilizer Lyophille Alpha 1–4 produced by Christ, Osterode am Harz, Germany. The LCST transitions were recorded with a UV–vis spectrometer Evolution 220 from Thermo Scientific, Waltham, MA, USA, equipped with a heating device from Harrick, Pleasantville, New York. The inclusion properties of the host molecules were investigated by head space gas chromatography with a Shimadzu GC-17A GC equipped with a head space unit from Shimadzu, Kyoto, Japan. Vials of 5 mL volume were used, the ratio between gas (V = 3.2 mL) and aqueous (V = 1.8 mL) phase was f = 1.77.

Materials. All chemicals (except CDs) were purchased from Sigma-Aldrich, Merck, Acros Organics, Fisher Scientific or TCI Europe and were used without further purification. α-, β- and γ-CD were kindly provided by Wacker Chemie AG, Munich, Germany and were used after drying overnight at 60 °C under reduced pressure. Human serum was kindly provided by University Hospital of Würzburg. All measurements were performed in saline HEPES-buffer solution (pH 7.4) with a NaCl concentration of 0.9 wt %.

3b1: Heptakis[6-deoxy-6-methylsulfanyl-2-(2-(2-(2-methoxyethoxy)ethoxy)ethyl)]-β-cyclodextrin:

[Graphic 1]

2.60 g (65 mmol) NaH (60 wt % dispersion in mineral oil, Sigma-Aldrich) was washed twice with 25 mL of n-pentane under N2 and stirred at rt for 1 h. After addition of 6.25 g (4.64 mmol) heptakis(6-deoxy-6-methylsulfanyl)-β-cyclodextrin dissolved in 130 mL of DMF, 17.8 g (65 mmol) 2-(2-(2-methoxyethoxy)ethoxy)ethyl iodide and 17.5 mg (0.05 mmol) tetra-n-butylammonium iodide were added and the resulting reaction mixture was stirred at 60 °C under N2 for 6 d. The reaction was quenched by the addition of 50 mL of ethanol and stirred at rt for further 30 min. The solvents were completely removed by vacuum distillation (bath temperature 70 °C, 1 mbar) and the residue was dissolved in 200 mL of water and neutralized by addition of 1 M HCl. The crude product was isolated by extraction with ethyl acetate at 70 °C using a Kutscher–Steudel extractor. The organic phase was concentrated in vacuo and the remaining residue was fractionized by column chromatography over 1.0 kg of silica (60 Å, 70–230 mesh, Fluka) with an ethyl acetate/methanol gradient (100/0 → 90/10 → 0/100 v/v) as eluent. The product (7.5 g, 68%) was obtained as a yellowish oil after complete removal of the eluent by vacuum distillation and drying at 60 °C in vacuo (0.03 mbar) for 3 d. TLC: Rf (EtOAc/MeOH 9:1 v/v) = 0.06; Rf (MeOH) = 0.57; 1H NMR δ/ppm (DMSO-d6, 400 MHz) 5.03 (d, 3J = 3.3 Hz, 1H, H-1), 4.89 (s, 1H, OH-3), 4.01–3.96 (m, 1H, H-8a), 3.79–3.69 (m, 3H, H-3, H-5, H-8b), 3.53 (s, 8H, H-8, H-9) 3.50 (m, 1H, H-4), 3.44–3.38 (m, 3H, H-2, H-9), 3.24 (s, 3H, O-CH3), 3.10–3.07 (m, 1H, H-6a), 2.75 (dd, 3J = 14.1 Hz, 7.8 Hz, 1H, H-6b), 2.08 (s, 3H, H-7); 13C NMR δ/ppm (DMSO-d6, 100 MHz) 100.5 (C-1), 85.5 (C-4), 71.3 (C-2, C-3, C-5), 69.8–69.6 (C-8, C-9), 58.0 (C-10), 35.0 (C-6), 16.0 (C-7); ESIMS m/z: 2390.90 [M + Na]+.

Supporting Information

Supporting Information File 1: Experimental procedures for CD derivatives 1b2, 3a1, 4a1, 3b2, 4b1, and 3c1.
Format: PDF Size: 268.3 KB Download


This work was funded by the Federal Ministry of Research and Technology (BMBF) Project No. 13N11804 in cooperation with Fresenius Kabi GmbH. The authors thank Devid Hero for his synthetic work and Annegret Engelke and Blandine Boßmann for their UV–vis and GC Headspace measurements. They also thank Sophie Fourmentin, Université du Littoral-Côte d'Opale Unité de Chimie Environmental et Interactions sur le Vivant, Dunkerque, France for measuring the Henry constants of sevoflurane and halothane, Antje Appelt-Menzel and Marco Metzger from Department of Tissue Engineering and Regenerative Medicine, University Hospital Würzburg, Germany for providing human serum and many helpful discussions.


  1. Wenz, G. Angew. Chem., Int. Ed. Engl. 1994, 33, 803–822. doi:10.1002/anie.199408031
    Return to citation in text: [1] [2]
  2. Loftsson, T.; Duchêne, D. Int. J. Pharm. 2007, 329, 1–11. doi:10.1016/j.ijpharm.2006.10.044
    Return to citation in text: [1]
  3. Brewster, M. E.; Loftsson, T. Adv. Drug Delivery Rev. 2007, 59, 645–666. doi:10.1016/j.addr.2007.05.012
    Return to citation in text: [1] [2]
  4. 2008/413/EC: Commission Decision of 26 May 2008 authorising the placing on the market of alpha-cyclodextrin as a novel food ingredient under Regulation (EC) No 258/97 of the European Parliament and of the Council (notified under document number C(2008) 19; Official Journal of the European Union, 2008; Vol. 51, pp. 12–16.
    Return to citation in text: [1]
  5. 2012/288/EU: Commission Implementing Decision of 1 June 2012 authorising the placing on the market of Gamma-Cyclodextrin as a novel food ingredient under Regulation (EC) No 258/97 of the European Parliament and of the Council (notified under document C(20; Official Journal of the European Union, 2012.
    Return to citation in text: [1]
  6. Kiss, T.; Fenyvesi, F.; Bácskay, I.; Váradi, J.; Fenyvesi, É.; Iványi, R.; Szente, L.; Tósaki, Á.; Vecsernyés, M. Eur. J. Pharm. Sci. 2010, 40, 376–380. doi:10.1016/j.ejps.2010.04.014
    Return to citation in text: [1] [2]
  7. Loftsson, T.; Brewster, M. E. J. Pharm. Pharmacol. 2010, 62, 1607–1621. doi:10.1111/j.2042-7158.2010.01030.x
    Return to citation in text: [1]
  8. Wiese, M.; Cordes, H.-P.; Chi, H.; Seydel, J. K.; Backensfeld, T.; Müller, B. W. J. Pharm. Sci. 1991, 80, 153–156. doi:10.1002/jps.2600800213
    Return to citation in text: [1]
  9. Wenz, G. Clin. Drug Invest. 2000, 19, Suppl., 21–25. doi:10.2165/00044011-200019002-00003
    Return to citation in text: [1]
  10. Kurkov, S. V.; Ukhatskaya, E. V.; Loftsson, T. J. Inclusion Phenom. Macrocyclic Chem. 2011, 69, 297–301. doi:10.1007/s10847-010-9756-x
    Return to citation in text: [1]
  11. Higuchi, T.; Connors, K. A. Adv. Anal. Chem. Instrum. 1965, 4, 117–212.
    Return to citation in text: [1]
  12. Del Valle, E. M. M. Process Biochem. 2004, 39, 1033–1046. doi:10.1016/S0032-9592(03)00258-9
    Return to citation in text: [1] [2]
  13. Vyas, A.; Saraf, S.; Saraf, S. J. Inclusion Phenom. Macrocyclic Chem. 2008, 62, 23–42. doi:10.1007/s10847-008-9456-y
    Return to citation in text: [1]
  14. Brewster, M. E.; Loftsson, T. Pharmazie 2002, 57, 94–101.
    Return to citation in text: [1]
  15. Tilloy, S.; Monnaert, V.; Fenart, L.; Bricout, H.; Cecchelli, R.; Monflier, E. Bioorg. Med. Chem. Lett. 2006, 16, 2154–2157. doi:10.1016/j.bmcl.2006.01.049
    Return to citation in text: [1]
  16. Carrier, R. L.; Miller, L. A.; Ahmed, I. J. Controlled Release 2007, 123, 78–99. doi:10.1016/j.jconrel.2007.07.018
    Return to citation in text: [1]
  17. Szente, L.; Szejtli, J. Adv. Drug Delivery Rev. 1999, 36, 17–28. doi:10.1016/S0169-409X(98)00092-1
    Return to citation in text: [1]
  18. Armstrong, D. W.; Li, W.; Chang, C. D.; Pitha, J. Anal. Chem. 1990, 62, 914–923. doi:10.1021/ac00208a006
    Return to citation in text: [1]
  19. Rekharsky, M. V.; Inoue, Y. Chem. Rev. 1998, 98, 1875–1918. doi:10.1021/cr970015o
    Return to citation in text: [1]
  20. Wenz, G. Beilstein J. Org. Chem. 2012, 8, 1890–1895. doi:10.3762/bjoc.8.218
    Return to citation in text: [1] [2]
  21. Thiele, C.; Auerbach, D.; Jung, G.; Wenz, G. J. Inclusion Phenom. Macrocyclic Chem. 2011, 69, 303–307. doi:10.1007/s10847-010-9741-4
    Return to citation in text: [1] [2]
  22. Steffen, A.; Thiele, C.; Tietze, S.; Strassnig, C.; Kämper, A.; Lengauer, T.; Wenz, G.; Apostolakis, J. Chem. – Eur. J. 2007, 13, 6801–6809. doi:10.1002/chem.200700661
    Return to citation in text: [1] [2]
  23. Wenz, G.; Strassnig, C.; Thiele, C.; Engelke, A.; Morgenstern, B.; Hegetschweiler, K. Chem. – Eur. J. 2008, 14, 7202–7211. doi:10.1002/chem.200800295
    Return to citation in text: [1] [2]
  24. Bom, A.; Bradley, M.; Cameron, K.; Clark, J. K.; van Egmond, J.; Feilden, H.; MacLean, E. J.; Muir, A. W.; Palin, R.; Rees, D. C.; Zhang, M.-Q. Angew. Chem., Int. Ed. 2002, 41, 265–270. doi:10.1002/1521-3773(20020118)41:2<265::AID-ANIE265>3.0.CO;2-Q
    Return to citation in text: [1]
  25. de Boer, H. D.; van Egmond, J.; van de Pol, F.; Bom, A.; Booij, L. H. D. J. Br. J. Anaesth. 2006, 96, 473–479. doi:10.1093/bja/ael013
    Return to citation in text: [1]
  26. Wang, H. M.; Wenz, G. Chem. – Asian J. 2011, 6, 2390–2399. doi:10.1002/asia.201100217
    Return to citation in text: [1]
  27. Wang, H. M.; Soica, C. M.; Wenz, G. Nat. Prod. Commun. 2012, 7, 289–291.
    Return to citation in text: [1]
  28. Şoica, C.; Dehelean, C.; Danciu, C.; Wang, H. M.; Wenz, G.; Ambrus, R.; Bojin, F.; Anghel, M. Int. J. Mol. Sci. 2012, 13, 14992–15011. doi:10.3390/ijms131114992
    Return to citation in text: [1]
  29. Wang, H. M.; Wenz, G. Beilstein J. Org. Chem. 2012, 8, 1644–1651. doi:10.3762/bjoc.8.188
    Return to citation in text: [1]
  30. Fourmentin, S.; Ciobanu, A.; Landy, D.; Wenz, G. Beilstein J. Org. Chem. 2013, 9, 1185–1191. doi:10.3762/bjoc.9.133
    Return to citation in text: [1] [2] [3] [4] [5]
  31. Delgado-Herrera, L.; Ostroff, R. D.; Rogers, S. A. CNS Drug Rev. 2001, 7, 48–120. doi:10.1111/j.1527-3458.2001.tb00190.x
    Return to citation in text: [1]
  32. Roewer, N.; Broscheit, J. Flurankomplex. Eur. Pat. Appl. EP2345427 A1, July 20, 2011.
    Return to citation in text: [1]
  33. Roewer, N.; Broscheit, J. Halogenated ether complex. U.S. Patent US 20120296077 A1, Nov 22, 2012.
    Return to citation in text: [1]
  34. Busold, M.; Mitterweger, S.; Regiert, M. E.; Sigl, H. 1:1, 2:1- oder 3:1-Komplex bestehend aus einem Cyclodextrin oder Cyclodextrinderivat und einem halogeniertem Ether, seine Herstellung und seine Verwendung als Schlafmittel. Ger. Patent DE 10 2010 042615 A1, April 19, 2012.
    Return to citation in text: [1]
  35. Falvey, P.; Lim, C. W.; Darcy, R.; Revermann, T.; Karst, U.; Giesbers, M.; Marcelis, A. T. M.; Lazar, A.; Coleman, A. W.; Reinhoudt, D. N.; Ravoo, B. J. Chem. – Eur. J. 2005, 11, 1171–1180. doi:10.1002/chem.200400905
    Return to citation in text: [1]
  36. Nolan, D.; Darcy, R.; Ravoo, B. J. Langmuir 2003, 19, 4469–4472. doi:10.1021/la034330j
    Return to citation in text: [1]
  37. Kauscher, U.; Stuart, M. C. A.; Drücker, P.; Galla, H.-J.; Ravoo, B. J. Langmuir 2013, 29, 7377–7383. doi:10.1021/la3045434
    Return to citation in text: [1]
  38. Felici, M.; Marzá-Pérez, M.; Hatzakis, N. S.; Nolte, R. J. M.; Feiters, M. C. Chem. – Eur. J. 2008, 14, 9914–9920. doi:10.1002/chem.200801429
    Return to citation in text: [1]
  39. Liu, Z.; Jiao, Y.; Wang, Y.; Zhou, C.; Zhang, Z. Adv. Drug Delivery Rev. 2008, 60, 1650–1662. doi:10.1016/j.addr.2008.09.001
    Return to citation in text: [1]
  40. Ballabh, P.; Braun, A.; Nedergaard, M. Neurobiol. Dis. 2004, 16, 1–13. doi:10.1016/j.nbd.2003.12.016
    Return to citation in text: [1]
  41. Kawabata, Y.; Matsumoto, M.; Tanaka, M.; Takahashi, H.; Irinatsu, Y.; Tamura, S.; Tagaki, W.; Nakahara, H.; Fukuda, K. Chem. Lett. 1986, 15, 1933–1934. doi:10.1246/cl.1986.1933
    Return to citation in text: [1]
  42. Parrot-Lopez, H.; Ling, C. C.; Zhang, P.; Baszkin, A.; Albrecht, G.; de Rango, C.; Coleman, A. W. J. Am. Chem. Soc. 1992, 114, 5479–5480. doi:10.1021/ja00039a100
    Return to citation in text: [1]
  43. Mazzaglia, A.; Donohue, R.; Ravoo, B. J.; Darcy, R. Eur. J. Org. Chem. 2001, 1715–1721. doi:10.1002/1099-0690(200105)2001:9<1715::AID-EJOC1715>3.0.CO;2-A
    Return to citation in text: [1] [2]
  44. Becker, M. M.; Ravoo, B. J. Chem. Commun. 2010, 46, 4369–4371. doi:10.1039/c0cc00616e
    Return to citation in text: [1]
  45. Chmurski, K.; Defaye, J. Supramol. Chem. 2000, 12, 221–224. doi:10.1080/10610270008027455
    Return to citation in text: [1]
  46. Tian, S.; D'Souza, V. T. Tetrahedron Lett. 1994, 35, 9339–9342. doi:10.1016/S0040-4039(00)78537-6
    Return to citation in text: [1]
  47. Kern, H.; Choi, S.; Wenz, G.; Heinrich, J.; Ehrhardt, L.; Mischnick, P.; Garidel, P.; Blume, A. Carbohydr. Res. 2000, 326, 67–79. doi:10.1016/S0008-6215(00)00024-0
    Return to citation in text: [1]
  48. de las Heras Alarcón, C.; Pennadam, S.; Alexander, C. Chem. Soc. Rev. 2005, 34, 276–285. doi:10.1039/b406727d
    Return to citation in text: [1]
  49. Szejtli, J.; Liptak, A.; Jodal, I.; Fügedi, P.; Nanasi, P.; Neszmelyi, A. Starch/Staerke 1980, 32, 162–164.
    Return to citation in text: [1]
  50. Yan, J.; Li, W.; Zhang, X.; Liu, K.; Wu, P.; Zhang, A. J. Mater. Chem. 2012, 22, 17424–17428. doi:10.1039/c2jm33328g
    Return to citation in text: [1]
  51. Lantz, A. W.; Wetterer, S. M.; Armstrong, D. W. Anal. Bioanal. Chem. 2005, 383, 160–166. doi:10.1007/s00216-005-0030-9
    Return to citation in text: [1]
  52. Landy, D.; Fourmentin, S.; Salome, M.; Surpateanu, G. J. Inclusion Phenom. Macrocyclic Chem. 2000, 38, 187–198. doi:10.1023/A:1008156110999
    Return to citation in text: [1]
  53. Soares, J. H. N.; Brosnan, R. J.; Fukushima, F. B.; Hodges, J.; Liu, H. Anesthesiology 2012, 117, 48–55. doi:10.1097/ALN.0b013e3182557cc9
    Return to citation in text: [1]
  54. Wallin, R. F.; Regan, B. M.; Napoli, M. D.; Stern, I. J. Anesth. Analg. (Paris) 1975, 54.
    Return to citation in text: [1] [2]
  55. Murata, J.; Yamashita, S.; Akiyama, M.; Katayama, S.; Hiaki, T.; Sekiya, A. J. Chem. Eng. Data 2002, 47, 911–915. doi:10.1021/je010322y
    Return to citation in text: [1]
Other Beilstein-Institut Open Science Activities